Oasmia Pharmaceutical is a Swedish speciality pharma company focusing on its proprietary XR-17 technology platform to develop novel formulations of well-established cytostatic oncology treatments for human and animal health. Key assets include Apealea (partnered with Elevar) and Docetaxel micellar.
Investment summary
Oasmia Pharmaceutical is focused on developing improved formulations of well-established cancer drugs through its proprietary XR-17 platform technology. Its solubility-enhancing technology has received validation though a global partnership deal for lead asset Apealea (Cremophor-free paclitaxel) with Elevar Therapeutics across a variety of cancer indications. Apealea is approved in Europe for second-line ovarian cancer and Elevar is in discussions with the FDA for the pathway to US approval. Oasmia is working on additional nanoparticle formulations, including docetaxel micellar (Phase Ib prostate cancer), and the development of innovative drugs (preclinical stage). Oasmia has an animal health pipeline with two clinical stage assets, Paccal Vet and Doxophos Vet. At 31 July 2020, Oasmia had net cash of SEK274m, giving a cash runaway into FY23.
Despite a slew of novel cancer drug treatments transforming care for many oncology indications, established chemotherapy regimens remain a cornerstone of treatment. Oasmia’s XR-17 technology is applicable to any solubility-limited drug, which includes 10–15 different cytostatic agents, and can potentially provide an improved formulation and profile.
